Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities
暂无分享,去创建一个
Kylie L. Gorringe | D. Etemadmoghadam | D. Bowtell | A. Mes-Masson | D. Huntsman | M. Köbel | D. Provencher | M. Carey | N. Hacker | I. Campbell | K. Gorringe | S. Hunter | A. de Fazio | T. Semple | P. Allan | D. Cheasley | C. Page | Magnus Zethoven | Abhimanyu Nigam | Marta Llauradó Fernández | A. Dawson | Yunkai Gao | A. De Fazio | Yunkai Gao
[1] Kylie L. Gorringe,et al. The molecular origin and taxonomy of mucinous ovarian carcinoma , 2019, Nature Communications.
[2] A. deFazio,et al. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. , 2019, Gynecologic oncology.
[3] Kylie L. Gorringe,et al. Molecular comparison of interval and screen‐detected breast cancers , 2019, The Journal of pathology.
[4] C. Collins,et al. Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target , 2019, Cancer Cell International.
[5] Li Zhou,et al. Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report. , 2018, Chinese clinical oncology.
[6] I. Campbell,et al. Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility , 2018, Genetics in Medicine.
[7] Sebastian M. Armasu,et al. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study , 2018, The journal of pathology. Clinical research.
[8] R. Bernards,et al. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors , 2018, Oncogene.
[9] D. Etemadmoghadam,et al. BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. , 2018, JCO precision oncology.
[10] C. Le Page,et al. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers , 2018, BMC Cancer.
[11] G. Jayson,et al. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer , 2018, Cancer Chemotherapy and Pharmacology.
[12] E. Thompson,et al. Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs , 2018, Breast Cancer Research.
[13] J. Campisi,et al. A novel suicide gene therapy for the treatment of p16Ink4a-overexpressing tumors , 2017, Oncotarget.
[14] Y. Okuno,et al. Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. , 2017, The American journal of pathology.
[15] P. Raman,et al. Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways , 2017, Oncotarget.
[16] Dale W. Garsed,et al. EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. , 2017, Cancer research.
[17] T. Choueiri,et al. Exceptional Response to Palbociclib in Metastatic Collecting Duct Carcinoma Bearing a CDKN2A Homozygous Deletion. , 2017, JCO precision oncology.
[18] Moriah H Nissan,et al. OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.
[19] P. Stephens,et al. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration. , 2017, The oncologist.
[20] D. Aoki,et al. Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer. , 2017, Oncology letters.
[21] D. Bodurka,et al. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Kun Yu,et al. PureCN: copy number calling and SNV classification using targeted short read sequencing , 2016, Source Code for Biology and Medicine.
[23] Trevor Hastie,et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. , 2016, American journal of human genetics.
[24] R. Scott,et al. Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] S. Kyo,et al. KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions , 2016, International journal of molecular sciences.
[26] S. Leung,et al. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[27] Guangchuang Yu,et al. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. , 2016, Molecular bioSystems.
[28] P. Tauchi-Nishi,et al. The LAST guidelines in clinical practice: implementing recommendations for p16 use. , 2015, American journal of clinical pathology.
[29] Kylie L. Gorringe,et al. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes , 2015, Oncotarget.
[30] D. Bodurka,et al. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Nicolai J. Birkbak,et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs , 2015, Biomarker Research.
[32] William Stafford Noble,et al. Escape from X Inactivation Varies in Mouse Tissues , 2015, PLoS genetics.
[33] Jos Jonkers,et al. CopywriteR: DNA copy number detection from off-target sequence data , 2015, Genome Biology.
[34] J. Gécz,et al. La FAM fatale: USP9X in development and disease , 2015, Cellular and Molecular Life Sciences.
[35] Pieter Wesseling,et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly , 2014, Genome research.
[36] Ming Chen,et al. A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology , 2014, OncoTargets and therapy.
[37] J. George,et al. Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver , 2014, Clinical Cancer Research.
[38] G. McVean,et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications , 2014, Nature Genetics.
[39] J. Shendure,et al. A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.
[40] S. Kalloger,et al. Stage II to IV Low-grade Serous Carcinoma of the Ovary Is Associated With a Poor Prognosis: A Clinicopathologic Study of 32 Patients From a Population-based Tumor Registry , 2013, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[41] Mauricio O. Carneiro,et al. From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.
[42] C. Le Page,et al. Specimen quality evaluation in Canadian biobanks participating in the COEUR repository. , 2013, Biopreservation and biobanking.
[43] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[44] Jiri Bartek,et al. Replication stress links structural and numerical cancer chromosomal instability , 2013, Nature.
[45] R. Hazan,et al. Correction: Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma , 2016, PloS one.
[46] M. Morgan,et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. , 2013, The Lancet. Oncology.
[47] I. Adzhubei,et al. Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2 , 2013, Current protocols in human genetics.
[48] A. Vincent-Salomon,et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.
[49] G. Mills,et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.
[50] ENCODEConsortium,et al. An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.
[51] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[52] Z. Szallasi,et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. , 2012, Cancer discovery.
[53] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[54] K. Kinzler,et al. Low‐grade serous carcinomas of the ovary contain very few point mutations , 2012, The Journal of pathology.
[55] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[56] A. Gonzalez-Perez,et al. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. , 2011, American journal of human genetics.
[57] J. George,et al. Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis , 2011, PloS one.
[58] Carlos Caldas,et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.
[59] D. Bodurka,et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. , 2008, Gynecologic oncology.
[60] Christopher R. Vakoc,et al. DOT1L/KMT4 Recruitment and H3K79 Methylation Are Ubiquitously Coupled with Gene Transcription in Mammalian Cells , 2008, Molecular and Cellular Biology.
[61] Tom H. Pringle,et al. The human genome browser at UCSC. , 2002, Genome research.
[62] O. Skalli,et al. Microtubule actin cross-linking factor 1, a novel target in glioblastoma. , 2017, International journal of oncology.
[63] S. Henikoff,et al. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.